

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1 Name and Address of Company

Knight Therapeutics Inc. ("**Knight**")
3400 De Maisonneuve West, suite 1055
Montréal, Québec
H3Z 3B8

Item 2 Date of Material Change

May 13, 2021

Item 3 News Release

A news release was disseminated by Globe Newswire on May 13, 2021 from Montréal, Québec.

Item 4 Summary of Material Change

Knight announced a leadership change.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On May 13, 2021, Knight announced that Samira Sakhia will assume the role of President and Chief Executive Officer, Knight Therapeutics Inc., effective September 1, 2021. Ms. Sakhia serves as Knight's President and Chief Operating Officer.

Jonathan Ross Goodman will assume the role of Executive Chairman.

Also effective September 1, 2021, James Gale will transition to the role of lead director.

5.2 Disclosure for Restructuring Transactions

N/A

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

This report is not being filed on a confidential basis.

Item 7 Omitted Information

N/A

Item 8 Executive Officer

Samira Sakhia
President and Chief Operating Officer
(514) 484-4483

Item 9 Date of Report

May 18, 2021